Rapid haemodynamic improvement following saruplase in recent massive pulmonary embolism

Thrombosis and Haemostasis

Volumn 79, Issue 2, 1998, Pages 264-267

  Pacouret, Gérard ^a   Barnes, Sarah J ^b   Hopkins, Gwyn ^b   Charbonnier, Bernard ^a  

^a SERVICE DE DERMATOLOGIE   (France)

^b GRÜNENTHAL GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR; SARUPLASE;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG ARTERY PRESSURE; LUNG EMBOLISM; LUNG RESISTANCE; PRIORITY JOURNAL;

EID: 0031934201     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614976     Document Type: Article

References (12)

1. Meyer G, Charbonnier B, Stern M, Brochier ML, Sors H. Thrombolysis in acute pulmonary embolism. In: Thrombolysis in Cardiovascular Disease. Julian D, Kubier W, Morris RM, Swan HJC, Collen D, Verstraete M, eds. Basel, New York: Marcel Dekker Company 1989; 337-60.
2. Petitpretz P, Simonneau G, Cerrina J, Musset D, Dreyfus M, Vandenbroek MD, Duroux P. Effects of a single bolus of Urokinase in patients with lifethreatening pulmonary emboli: a descriptive trial. Circulation 1984; 70: 861-6.
3. Meyer G, Sors H, Charbonnier B, Kasper W, Bassand JP, Kerr IH, Lesaffre E, Vanhove P, Verstraete M. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicentre double-blind trial. J Am Coll Cardiol 1992; 19: 239-45.
4. Sors H, Pacouret G, Azarian R, Meyer G, Charbonnier B, Simonneau G. Hemodynamic effects of bolus versus 2 h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest 1994; 106: 712-7.
5. PRIMI Trial Study Group. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1989; 1: 863-8.
6. Meneveau N, Bassand JP, Schiele F, Boura Y, Anguenot T, Bernrd Y, Schultz R. Safety of thrombolytic therapy in elderly patients with massive pulmonary embolism: a comparison with non elderly patients. J Am Coll Cardiol 1993; 2: 1075-9.
7. Flohé L. Recombinant human pro-urokinase (non-glycosylated). Drugs Future 1986; 11: 851-2.
8. Miller GAH, Sutton GS, Kerr IH, Gibson RV, Honey M. Comparison of streptokinase and heparin in treatment of isolated massive pulmonary embolism. Br Med J 1971; 2: 681-4.
9. Brochier M, Raynaud P, Fauchier JP, Charbonnier B, Latour F, Alison A, Pellois A, Planiol T. Comparison between lung scans and pulmonary angiograms in the evaluation of the perfusion defect in massive and submassive pulmonary embolism. Prog Resp Res (Karger. Basel) 1980; 13: 120-6.
10. Vermeer F, Bär FW, Windeler J, Schenkel W. Saruplase: a new fibrin specific thrombolytic agent. Final results of the PASS study (1698 patients). Circulation 1993; 88: I.292.
11. Diehl JL, Meyer G, Igual J, Collignon AMA, Giselbrecht M, Even P, Sors H. Effectiveness and safety of bolus administration of alteplase in massive pulmonary embolism. Am J Cardiol 1992; 70: 1477-80.
12. Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AG, Gent M. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990; 98; 1473-9.